Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2016-10-18 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第一届董事会第十八次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the first board meeting of Betta Pharmaceuticals Co., Ltd., detailing decisions made by the board regarding stock issuance and authorization for an IPO on the Growth Enterprise Market. It includes voting results and signatures of board members. There is no indication of financial statements, audit information, or detailed financial performance data. The content is focused on board decisions and approvals, which aligns with announcements related to board or management information rather than full reports or regulatory filings. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and specific to board resolutions, not a full report or announcement of a report publication.
2016-10-18 Chinese
国浩律师（杭州）事务所关于公司首次公开发行股票并在创业板上市之补充法律意见书（二）
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the initial public offering (IPO) and listing of a company (贝达药业股份有限公司) on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It discusses the company's qualifications, approvals, authorizations, shareholder structure, capital changes, and compliance with relevant laws and regulations. The document references audit reports and internal control reports but is primarily a legal opinion related to the IPO process. It is not a financial report, earnings release, or management discussion. It is also not a brief announcement or a proxy statement. Given the nature of the document as a legal opinion letter related to the IPO and listing process, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory and compliance filings that do not fit other specific categories.
2016-10-18 Chinese
国浩律师（杭州）事务所关于公司首次公开发行股票并在创业板上市之补充法律意见书（三）
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the initial public offering (IPO) and listing of Betta Pharmaceuticals Co., Ltd. on the Growth Enterprise Market (创业板). It addresses regulatory feedback from the China Securities Regulatory Commission (CSRC) and provides extensive legal clarifications and confirmations related to the IPO process, including shareholder structure, patent ownership, cooperation agreements, and control of the company. The document is a supplementary legal opinion letter (补充法律意见书（三）) which supplements previous legal opinion letters and lawyer work reports related to the IPO. It is not a financial report, earnings release, or management discussion, but a legal document specifically prepared for regulatory compliance and disclosure in the IPO process. This type of document fits best under the category of Regulatory Filings (RNS), as it is a regulatory compliance document that does not fit into other specific categories like Annual Report, Audit Report, or Capital Update. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or certification, so it is not RPA or a certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-10-18 Chinese
内部控制鉴证报告
Regulatory Filings
2016-10-18 Chinese
2016年第一次临时股东大会会议决议
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as the resolution of the 2016 first extraordinary general meeting of shareholders of Betta Pharmaceuticals Co., Ltd. It contains voting results on proposals related to the company's initial public offering and authorization extensions. The content is about official shareholder meeting decisions and voting outcomes, not a full annual report or financial statements. It is not a proxy solicitation or presentation but a formal record of voting results at a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results, confirming this classification.
2016-10-18 Chinese
2014年第一次临时股东大会会议决议
Regulatory Filings
2016-10-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.